Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T.

Oral Oncol. 2019 Aug 23;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. [Epub ahead of print]

PMID:
31450171
2.

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.

Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.

3.

Induction chemotherapy in head and neck cancers: Results and controversies.

Gau M, Karabajakian A, Reverdy T, Neidhardt EM, Fayette J.

Oral Oncol. 2019 Aug;95:164-169. doi: 10.1016/j.oraloncology.2019.06.015. Epub 2019 Jun 25. Review.

PMID:
31345386
4.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

5.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
6.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators.

Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080.

PMID:
30865223
7.

Systematic screening for occupations and occupational exposures in head and neck squamous cell carcinoma patients.

Deneuve S, Charbotel B, Massardier-Pilonchéry A, Fort E, Milliet-Baude C, Pérol O, Fayette J, Zrounba P, Fervers B.

Eur Arch Otorhinolaryngol. 2019 Mar;276(3):857-864. doi: 10.1007/s00405-018-05275-7. Epub 2019 Jan 3.

PMID:
30607561
8.

L’immunothérapie dans les cancers ORL.

Reverdy T, Gau M, Karabajakian A, Neidhardt EM, Fayette J.

Bull Cancer. 2018 Dec;105 Suppl 1:S35-S42. doi: 10.1016/S0007-4551(18)30388-6. Review. French.

PMID:
30595197
9.

Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief.

Karabajakian A, Gau M, Reverdy T, Neidhardt EM, Fayette J.

Cancers (Basel). 2018 Dec 22;11(1). pii: E15. doi: 10.3390/cancers11010015. Review.

10.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

11.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E.

Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Review.

12.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
13.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

14.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

15.

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.

Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J.

Oncotarget. 2018 Apr 24;9(31):22038-22046. doi: 10.18632/oncotarget.25157. eCollection 2018 Apr 24.

16.

Immunotherapy in head and neck cancer: a new paradigm.

Reverdy T, Karabakakian A, Gau M, Fayette J.

Anticancer Drugs. 2018 Jun;29(5):385-386. doi: 10.1097/CAD.0000000000000607. No abstract available.

PMID:
29649037
17.

Nivolumab in recurrent/metastatic head and neck cancers.

Karabajakian A, Reverdy T, Gau M, Fayette J.

Future Oncol. 2018 Mar;14(7):603-609. doi: 10.2217/fon-2017-0440. Epub 2017 Nov 13.

PMID:
29130342
18.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.

J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.

19.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

20.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, Sablin MP, Even C, Orlandini F, Juzyna B, Bellera C.

Oncotarget. 2017 Mar 4;8(31):51830-51839. doi: 10.18632/oncotarget.15901. eCollection 2017 Aug 1.

21.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

22.

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's).

Bétrian S, Bergeron C, Blay JY, Bompas E, Cassier PA, Chevallier L, Fayette J, Girodet M, Guillemet C, Le Cesne A, Marec-Berard P, Ray-Coquard I, Chevreau C.

Clin Sarcoma Res. 2017 May 10;7:10. doi: 10.1186/s13569-017-0076-4. eCollection 2017.

23.

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P.

Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210.

24.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C.

Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.

PMID:
28419181
25.

Chemotherapy for recurrent/metastatic head and neck cancers.

Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J.

Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Review.

PMID:
28166090
26.

Chemotherapy for localized head and neck squamous cell cancers.

Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J.

Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Review.

PMID:
28134662
27.

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.

Gibelin C, Avrillon V, De La Fouchardiere A, Mc Leer-Florin A, Lantuejoul S, Fayette J.

Lung Cancer. 2016 Dec;102:42-43. doi: 10.1016/j.lungcan.2016.10.005. Epub 2016 Oct 19.

PMID:
27987587
28.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

29.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

30.

Multilocus Sequence Typing of Strains of Bacterial Spot of Lettuce Collected in the United States.

Fayette J, Raid R, Roberts PD, Jones JB, Pernezny K, Bull CT, Goss EM.

Phytopathology. 2016 Nov;106(11):1262-1269. Epub 2016 Aug 18.

31.

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.

Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, Céruse P.

Oncotarget. 2016 Jun 14;7(24):37297-37304. doi: 10.18632/oncotarget.8934.

32.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

33.

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P.

Drug Des Devel Ther. 2015 Nov 26;9:6203-10. doi: 10.2147/DDDT.S81488. eCollection 2015.

34.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR.

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

35.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557.

36.

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.

Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, Henry S, Schilf A, Bourhis J.

Ann Oncol. 2015 Sep;26(9):1941-7. doi: 10.1093/annonc/mdv268. Epub 2015 Jun 24.

PMID:
26109631
37.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

PMID:
25892145
38.

Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck.

Guenne C, Fayette J, Cosmidis A, Fuchsmann C, Tartas S, Favrel V, Céruse P.

Drug Des Devel Ther. 2014 Dec 12;8:2549-53. doi: 10.2147/DDDT.S70451. eCollection 2014.

39.

Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors.

Perrier L, Kembou NS, Rascle P, Bui B, Morelle M, Ranchère VD, Terrier P, Neuville A, Decouvelaere AV, Le Cesne A, Gomez F, de la Fouchardière C, Meeus P, Trédan O, Pérol M, Fayette J, Neidhardt EM, Biron P, Boyle HJ, Marec BP, Farsi F, Ducimetière F, Blay JY, Ray CI, Coindre JM.

Value Health. 2014 Nov;17(7):A624. doi: 10.1016/j.jval.2014.08.2219. Epub 2014 Oct 26. No abstract available.

40.

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.

Péron J, Polivka V, Chabaud S, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, Fayette J.

BMC Cancer. 2014 Jul 10;14:504. doi: 10.1186/1471-2407-14-504.

41.

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.

Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE.

Ann Oncol. 2014 Sep;25(9):1813-20. doi: 10.1093/annonc/mdu216. Epub 2014 Jun 13.

42.

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P, Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T, Bexon A, Nutting C; NA EMD 1201081 Study Group.

Invest New Drugs. 2014 Dec;32(6):1278-84. doi: 10.1007/s10637-014-0117-2. Epub 2014 Jun 4.

PMID:
24894651
43.

[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care].

Fayette J, Pointreau Y, Bourhis J, Lefebvre JL.

Bull Cancer. 2014 May 1;101(5):438-44. doi: 10.1684/bdc.2014.1945. Review. French.

PMID:
24886894
44.

A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.

Céruse P, Cosmidis A, Belot A, Rabilloud M, Fuchsmann C, Poupart M, Ramade A, Tartas S, Favrel V, Pommier P, Zrounba P, Fayette J.

Anticancer Drugs. 2014 Sep;25(8):970-5. doi: 10.1097/CAD.0000000000000126.

PMID:
24849707
45.

[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].

Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J.

Bull Cancer. 2013 Oct;100(10):983-97. doi: 10.1684/bdc.2013.1829. Review. French.

PMID:
24126183
46.

[Identification of occupational exposures among patients with lung cancer].

Cellier C, Charbotel B, Carretier J, Rebattu P, Fayette J, Pérol M, Claude L, Philip T, Fervers B.

Bull Cancer. 2013 Jul-Aug;100(7-8):661-70. doi: 10.1684/bdc.2013.1783. French.

PMID:
23831888
47.

Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.

Fayette J, Bonnin N, Ferlay C, Lallemant B, Ramade A, Favrel V, Zrounba P, Chabaud S, Pommier P, Poupart M, Céruse P.

Anticancer Drugs. 2013 Jul;24(6):623-9. doi: 10.1097/CAD.0b013e328360b9d6.

PMID:
23542750
48.

Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas.

el Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY.

Target Oncol. 2013 Dec;8(4):261-9. doi: 10.1007/s11523-012-0249-2. Epub 2013 Jan 25.

PMID:
23354874
49.

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R.

Eur J Cancer. 2013 May;49(7):1609-18. doi: 10.1016/j.ejca.2012.11.023. Epub 2012 Dec 19.

PMID:
23265705
50.

Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.

Péron J, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, Fayette J.

Anticancer Drugs. 2012 Nov;23(10):1107-11.

PMID:
22954504

Supplemental Content

Loading ...
Support Center